课题基金 / 基金详情

Synthesis of non-brain-permeant inhibitor of LZK

Synthesis of non-brain-permeant inhibitor of LZK
LZK非透脑抑制剂的合成
批准号：
10001308
负责人：
Matthew Hall
金额：
$13.27万
依托单位：
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES
依托单位国家：
美国
项目类别：
财政年份：
--
资助国家：
美国
项目状态：
未结题
起止时间：
至
来源：
https://reporter.nih.gov/project-details/10001308
关键词：
Animal ModelAnimalsBrainChemicalsCollaborationsDiseaseExtramural ActivitiesGenomicsGoalsHead and Neck CancerInformaticsModelingMusPharmaceutical ChemistryPhosphotransferasesPlasmaProcessResearchTestingUnited States National Institutes of HealthWorkdrug discoveryinhibitor/antagonistkinase inhibitornew therapeutic targetscreeningsmall moleculesmall molecule inhibitorsmall molecule therapeuticstherapeutic development

项目摘要

项目成果

Matthew Hall的其他基金

相似基金

相关文献

中文摘要
翻译
LZK已被确定为头颈癌的新治疗靶点。该项目旨在合成LZK激酶的小分子抑制剂，这种小分子抑制剂是非大脑的，旨在进行动物实验。 在此期间，之前合成的LZK抑制剂在PK小鼠研究中进行了测试，它们都显示出较高的脑/血浆比率。因此，目前正在进行耐受性筛查，以检查这些抑制剂是否真的对小鼠有毒。如果不是，那么这些化合物仍然可以用于高级动物模型。
英文摘要
LZK has been identified as a novel therapeutic target in head and neck cancer. This project aims to synthesize small molecule inhibitors of the LZK kinase that are non-brain permeant to enable proof-of-concept animal studies. During this period, the previously synthesized LZK inhibitors were tested in a PK mouse study, and they all still showed a high brain to plasma ratio. As such, a tolerability screen is now underway to examine whether these inhibitors are indeed toxic to mice. If not, then these compounds can still be used in advanced animal models.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
BRD4 Inhibitors as Potential Therapeutics for Oncology
qHTS to Identify Inhibitors of Mutant and Wildtype NSD2
qHTS to Identify Activators and Inhibitors of Wip1
qHTS to Identify Inducers of Oligodendrocyte-precursor cell (OPC) Remyelination
海外基金